RAC (US) Examination Study Checklist



Similar documents
Roles & Responsibilities of the Sponsor

RAPS ONLINE UNIVERSITY

NRA FUNCTION IN CONTROLLING VACCINES IN CLINICAL TRIAL AND MARKETING AUTHORIZATION INDONESIA 2013 DVI MEETING 9 11 APRIL

Health Canada s GCP Compliance Program Part 2. GCP Information Sessions November 2010

GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group

Total Product Lifecycle Solutions from NSF Health Sciences Medical Devices

Overview of Medical Device Design Controls in the US. By Nandini Murthy, MS, RAC

IVD Regulation Overview. Requirements to Assure Quality & Effectiveness

2.2 Roles and Responsibilities in the Conduct and Assessment of Clinical Trials

Application Submitted on Received on Supplement type NDA /S-005 July 24, 2008 July 25, 2008 Changes Being Effected

Quality Agreement. by and between. Supplier Name. Address: and. Client Name: Address:

The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers.

Importing pharmaceutical products to China

U.S. Food and Drug Administration

Establishment of a Quality Systems approach to Clinical Site Management An Overview of Standard Operating Procedures (SOPs)

February 2006 Procedural

Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013

How to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

Good Clinical Practice 101: An Introduction

Comparison between FDA QSR and ISO 13485

Making SOP Training More Effective

Overview of Drug Development: the Regulatory Process

Regulatory Affairs Professional Development Framework AN OVERVIEW

Study Start-Up SS STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV)

Clinical Investigator Inspections and FDA-483 Observations

Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials

NDA /S-008 SUPPLEMENT APPROVAL

LIBRARY GUIDE: Clinical Pharmaceutical

Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions

Presented by Rosemarie Bell 24 April 2014

Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE

History and Principles of Good Clinical Practice

Clinical evaluation Latest development in expectations EU and USA

FDA Presentation - Society for Clinical Research Sites

Pharmaceutical and Biomedical Due Diligence Checklist

Challenges in the Regulation of Pediatric Clinical Trials

PMAs, 510(k)s, and Advanced IDE Topics

LIBRARY GUIDE: Clinical Medical Device

Quality Agreements: Contractual Commitments by CROs to Deliver High-Quality Work

Auditing as a Component of a Pharmaceutical Quality System

The Regulatory Binder/Trial Master File: Essential Records for the Conduct of a Clinical Trial

ORACLE CONSULTING GROUP

ectd Digital Handbook Table of Contents

Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives. Barry A. Friedman, Ph.D. Consultant

PREP Course #27: Medical Device Clinical Trial Management

Signature Requirements for the etmf

UT Health Science Center at San Antonio Research/Grant Records

Table of Contents. Preface 1.0 Introduction 2.0 Scope 3.0 Purpose 4.0 Rationale 5.0 References 6.0 Definitions

Barnett International and CHI's Inaugural Clinical Trial Oversight Summit June 4-7, 2012 Omni Parker House Boston, MA

REGULATORY ENVIRONMENT

Objectives. Monitoring & Auditing of Clinical Trials. Overview. Pre-study Qualification Visit. Industry-sponsored Trials

PDUFA REAUTHORIZATION PERFORMANCE GOALS AND PROCEDURES FISCAL YEARS 2013 THROUGH 2017

The Monitoring Visit. Denise Owensby, CCRP Sr. Clinical Research Coordinator Clinical & Translational Science Center University of California, Davis

gsop Vendor Assessment SOP page 1 of 10

Overview of Pre-Approval Inspections

Health Products and Food Branch.

Health Canada s GCP Compliance Program. GCP Information Sessions November 2010

A clinical research organization

A Natural Products Association Presents. SQF Certification. Josh Grauso Technical Sales Director UL Registrar

Topics for today. Issues: Regulatory Obligations Post-marketing Adverse Event Reporting; MDRs and Safety Reports. Post-marketing Submissions

CLINICAL RESEARCH PROTOCOL CHECKLIST

International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation

Conducting a Gap Analysis on your Change Control System. Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc.

CLINICAL RESEARCH ORGANIZATION

BUILDING QUALITY INTO CLINICAL TRIALS AN FDA PERSPECTIVE

The Clinical Trials Regulation EU No 536/2014: and Phase I trials

INSIDE STORY FOR REVIEW OF DMF AND DOSSIERS BY REGULATORY AUTHORITIES. (Part I: ANDA, NDA & DMF)

Premarket Approval Applications (PMAs), Product Development Protocols (PDPs), and Humanitarian Device Exemptions

OECD Recommendation on the Governance of Clinical Trials

Regulation and Risk Management of Combination Products

The Study Site Master File and Essential Documents

Monitoring & Auditing of Clinical Trials. Sponsored by Center for Cancer Research National Cancer Institute

Library Guide: Pharmaceutical GMPs

ASTRAZENECA GLOBAL POLICY QUALITY AND REGULATORY COMPLIANCE

Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry

Annex 7 Guidelines for the preparation of a contract research organization master file

What is necessary to provide good clinical data for a clinical trial?

Guidance for IRBs, Clinical Investigators, and Sponsors. Considerations When Transferring Clinical Investigation Oversight to Another IRB

Extemporaneously Prepared Early Phase Clinical Trial Materials

Essential Documents for the Conduct of a Clinical Trial. Debra Dykhuis Associate Director RSO

Medical Device Training Program 2015

The Medical Device Industry in Korea: Strategies for Market Entry

ICRIN Seminar on EU Regulation of Clinical Trials

100 HOT TOPICS FOR DISSERTATION FOR PG DIPLOMA/ DEGREE IN REGULATORY AFFAIRS

Developing a Mobile Medical App? How to determine if it is a medical device and get it cleared by the US FDA

Combination Products Regulation in the United States

CATEGORY Advertising. CATEGORY Biopharmaceutics. CATEGORY Biosimilarity

COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS

ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014

Audit, Business Risk and Compliance Committee Charter Pact Group Holdings Ltd (Company)

FAMI-QS Certification Rules for Operators. Rules for Operators

The Concept of Quality in Clinical Research. Dorota Śwituła Senior Clinical Quality Assurance Advisor

1

Testing Automated Manufacturing Processes

An FDA Perspective on Post- Approval Change Management for PAT and RTRT

TRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP

4.1 Objectives of Clinical Trial Assessment

Core Training Outline

Transcription:

RAC (US) Examination Study Checklist Instructions: Use this checklist to track your progress when preparing for the RAC (US) certification examination. When you begin your studying, each task statement and place a checkmark in the box that best describes your study needs for each task. If you are not familiar with or do not regularly perform the content in the listed task, you most likely need and should check the box. If the content listed is a task that you perform regularly as part of your job, you most likely need less and should check the Need box. Once you your of the content in the listed task, check the box. Domain I: Strategic Planning (approximately 28% of exam) 1. Evaluate proposed products for regulatory classification (drug/device/biologic/combination/otc etc.) /jurisdiction (CDER/CDRH/CBER etc.) 2. Monitor and assess the regulatory environment (product specific guidances, competitor products etc.) to propose regulatory path forward (generic/otc/predicate device etc.) 3. Evaluate US regulatory implications for non US (global) development and marketing 4. Provide input to FDA, industry (PhRMA, AdvaMed etc.) and standards (USP, ASTM, ICH etc.) organizations to influence the US regulatory environment (legislation, regulations, guidance documents, standards etc.) 5. Determine requirements (local, national, international) and options for regulatory submissions (NDA/BLA/PMA/510k, electronic/paper, 505(b)(2), etc.), approvals (priority, user fees, etc.), and compliance activities (registration, listings, etc.). 6. Advise management on timelines, benefits/risk assessment and financial implications of the proposed regulatory strategy 7. Investigate and communicate the availability of incentives (pediatric, orphan, fast track, HDE etc.) to support product development 8. Develop optimal strategy for Agency interactions during product development and life cycle management 9. Advise internal stakeholders (marketing, manufacturing, R&D etc.) regarding current/pending guidances, regulations, Agency/industry initiatives etc. to ensure regulatory strategy is in alignment with company objectives. 10. Consult with marketing/project team to develop intended use and claims (target product profile)

11. Assess quality systems (e.g., CE marking, ICH, GMP/QSR, ISO, etc.) by performing audits to determine compliance to Quality System Regulations (QSR) and Drug GMP, assuring compliance to established SOPs for QSR and drug GMPs [e.g., failure investigations, etc], and making recommendations for improvement of quality systems, based on audit findings and QSR or GMP requirements. 12. Develop/deliver/assure in house training programs for all company personnel for regulatory compliance (Refers to GXP). 13. Assure implementation and documentation of training programs including identification of training needs (jobspecific and general GMP training) and training schedules. 14. Provide trainers with updated information on regulatory requirements to incorporate in on going training programs. 15. Conduct regulatory due diligence and advise senior management during product or company acquisitions and collaborations 16. Ensure regulatory obligations are met for In and Outlicensing of products 17. Ensure regulatory obligations are met for contract activities (manufacturing, complaint handling, regulatory operations etc.) Domain II: Pre-Approval (approximately 25% of exam) 1. Determine test requirements (GLP/non GLP, biocompatibility, carcinogenicity studies specific to drug/biologic/device, etc.) and identify applicable guidances 2. Ensure compliance with nonclinical safety (GLPs) and applicable performance standards (ISO, ASTM, ANSI, ICH etc.) 3. Determine adequacy of nonclinical data and risk analysis to support initiation of clinical trials including any appropriate risk management 4. Assess quality systems (e.g., CE marking, ICH, GMP/QSR, ISO, etc.) by performing audits to determine compliance to Quality System Regulations (QSR) and Drug GMP, assuring compliance to established SOPs for QSR and drug GMPs [e.g., failure investigations, etc], and making recommendations for improvement of quality systems, based on audit findings and QSR or GMP requirements. 5. Determine requirements with regard to clinical safety and efficacy (GCPs) 6. Ensure compliance with all clinical standards (GCPs, (clinical trial monitoring and auditing), IRBs, safety reporting, informed consent, financial disclosure, etc.)

7. Advise project team of regulatory recommendations for ongoing aspects of clinical trials/investigations (amendments to protocol etc.) 8. Identify non US country specific requirements for impact to US submissions (IND/IDE, annual report etc.) 9. Prepare and/or information included in IND/IDE submission such as: label, clinical investigation plan/protocol, case report form, investigators brochure, informed consent etc. 10. Ensure that any identified safety risks have been appropriately addressed with the clinical development program 11. Ensure that CFR requirements for adverse event reporting are established and being followed 12. Evaluate need for and contribute to the development of Pediatric Development Plan and/or waivers/deferrals, Orphan Designation Applications etc. 13. Determine regulatory requirements for manufacturing /quality system certifications (clinical trial supplies, manufacture, dosage forms, device classification, DMFs, etc.) 14. Ensure compliance with cgmps and QSR (SOPs, record retention, calibration etc.) 15. Verify device Design History File complies with regulatory requirements including risk management 16. Ensure regulatory compliance of manufacture and release of investigational products for clinical use 17. ness of documentation to support IND/IDE submissions 18. Ensure specifications for testing of API/drug substance/drug product and documentation of raw materials (novel excipients, animal derived materials etc.) comply with regulatory requirements 19. Ensure specifications for device components, manufacturing process, and product have been defined and meet regulatory requirements (including product and quality system software) 20. Evaluate manufacturing changes for compliance with appropriate change control systems/process and determine regulatory filing strategy 21. and monitor regulatory compliance for suppliers (contract manufacturers, CROs etc.) 22. Prepare pre market submissions (IDE/IND) and masterfiles for drugs/biologics/devices including investigational labeling 23. Guide project regarding submission format (CTD/eCTD etc.) 24. application for ness according to refuseto file guidelines

25. Negotiate/interact as appropriate with Agency during development/submission process (Pre IDE/IND, End of Phase 2, Meetings, Respond to Agency comments etc.) 26. Monitor and maintain ongoing IDE/IND applications (e.g., amendments, annual reports, updates) 27. Determine requirements for export/import of investigational products (customs, USDA, etc) 28. Ensure that the identified risks have been appropriately flagged and monitored 29. Initiate process to obtain non proprietary (USAN) and proprietary names Domain III: Approval (approximately 24% of exam) 1. Assess and verify adequacy of nonclinical data to support approval 2. Assemble nonclinical reports and prepare nonclinical summary documentation as appropriate 3. Assess the adequacy of clinical safety and efficacy data to support approval and desired label claims 4. Assemble clinical reports submission and prepare summary documentation as appropriate 5. Ensure clinical trial monitoring and clinical trial audits are performed 6. Assess and verify the adequacy of data to support submission approval and desired label claims/product specifications 7. Assess and verify the readiness of the drug/device manufacturing facility for PAI (Ensure compliance with GMP and QSR) 8. Assemble CMC documentation submission and prepare summary documentation as appropriate 9. Prepare and schedule pre submission meetings with the Agency at the appropriate stage of the submission (e.g., pre IND/IDE, end of Phase 2, etc.) to reach agreement on content, format, and other issues/proposals. 10. Guide project regarding submission format (CTD/eCTD, paper etc.) 11. Negotiate/interact as appropriate with Agency during the submission process (120 Day Safety Report, Respond to Agency comments, 100 Day etc.) 12. Prepare for and participate in Advisory Committee Meeting/Advisory Panel Meeting if requested 13. Drive the creation of draft labeling that meets regulatory requirements and negotiate final labeling with FDA at end of period (SPL)

14. Develop post approval regulatory plans and negotiate agreement with FDA (eg risk evaluation and mitigation strategy (REMS) and post market clinical follow up plan) 15. Provide guidance on FDA practices and current thinking (refusal to file, priority assignment, FDAs Best Practices, etc.) Domain IV: Post-Approval (approximately 23% of exam) 1. Submit required licensing fees, drug listings, periodic reports and updates (e.g., PSURS, masterfiles, etc.) 2. Comply with product post marketing approval requirements/condition of approval studies (Phase IV Studies) 3. Prepare, implement and monitor strategy for alerts/notifications/recalls/market withdrawal 4. Advise management on alerts/notifications/recalls 5. Provide regulatory input on post approval change management 6. Assess documentation to support product and process changes and determine regulatory category of change (PAS, CBE, Annual Reports etc) 7. Prepare and submit supplements/design change applications and notifications to NDA, BLA, PMA 8. Maintain and record changes to the technical file/design dossier or NDA/BLA. 9. Ensure compliance with Risk Evaluation and Mitigation Strategy (REMS). 10. Evaluate reports of product complaints 11. Ensure that appropriate systems are in place to document and track product complaints and ADR reports 12. Ensure implementation of necessary corrective actions based on results of inspections, audits, failure analysis, and consent decrees 13. Report product safety issues/failures to regulatory agencies as required [e.g. ADEs] 14. adverse drug reaction reports and medical device reports 15. and approve revised labeling and claims, public communications, press releases, advertising, and promotional items for regulatory compliance 16. Evaluate data to support comparative claims in advertising and implications of off label use 17. Ensure compliance with regulatory requirements for supply, handling, distribution, import and export of materials. 18. Ensure compliance with applicable requirements/regulations for distribution of controlled

substances 19. regulatory aspects of contracts for product distribution (e.g., product complaints, product tracking, etc.) 20. Advise on the issues related to drug/product/lot releases (Annual Product, Device History Record) 21. Advise management regarding the regulatory impact of a crisis event 22. Develop regulatory plan to address the crisis event. 23. Advise management on regulatory implications of proposed crisis resolution strategies 24. Facilitate coordination of outside consultants and company personnel in response to Agency comments (PAI, 483 responses, conduct of clinical studies etc.) 25. Negotiate with Agency wording of inspection findings 26. Manage/accompany/chaperone inspection teams or auditors 27. Advise internal functional groups regarding regulatory compliance (e.g., FDA 483's, warning letters, and consent decrees) and communicate corrective follow up actions to management 28. Prepare strategy/briefing documents for panel hearings and informational meetings (Advisory Committee) 29. Communicate/refer external requests for information 30. Develop Freedom of Information Act strategy regarding confidentiality and protection of proprietary information and document requests